Medications for Mast Cell Activation Syndrome (MCAS)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Mast Cell Activation Syndrome (MCAS).
Found 3 Approved Drugs for Mast Cell Activation Syndrome (MCAS)
Imatinib
Brand Names
Imkeldi, Gleevec
Imatinib
Brand Names
Imkeldi, Gleevec
Form: Tablet, Solution
Method of administration: Oral
FDA approval date: May 15, 2001
Classification: Kinase Inhibitor
Imatinib mesylate tablets are a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Ayvakit
Generic Name
Avapritinib
Ayvakit
Generic Name
Avapritinib
Form: Tablet
Method of administration: Oral
FDA approval date: January 09, 2020
Classification: Kinase Inhibitor
AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
Rydapt
Generic Name
Rydapt
Rydapt
Generic Name
Rydapt
Form: Capsule
Method of administration: Oral
FDA approval date: April 28, 2017
Classification: Kinase Inhibitor
RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
Showing 1-3 of 3
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances